REFERENCES
[1] Chi Z, Li S, Sheng X, Si L, Cui C, Han M, et al. Clinical
presentation, histology, and prognoses of malignant melanoma in ethnic
Chinese: a study of 522 consecutive cases. BMC Cancer 2011; 11: 85.
[2] Yin GF, Guo W, Chen XH, Liu ZY, Huang ZG. Clinical
characteristic and prognostic analyses of 117 cases of head and neck
mucosal melanoma. Chin J Otorhinolaryngol Head Neck Surg 2018; 53(9):
668–674.
[3] Ngoenkam J, Schamel WW, Pongcharoen S. Selected signalling
proteins recruited to the T-cell receptor-CD3 complex. Immunology 2018;
153(1): 42–50.
[4] Maimela NR, Liu S, Zhang Y. Fates of CD8+ T cells in tumor
microenvironment. Comput Struct Biotechnol J 2018; 17: 1–13.
[5] Ostroumov D, Fekete-Drimusz N, Saborowski M, Kühnel F, Woller N.
CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol
Life Sci 2018; 75(4): 689–713.
[6] Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo
HF, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses
correlate with clinical benefit in advanced melanoma patients treated
with ipilimumab. Proc Natl Acad Sci USA 2011; 108: 16723–8.
[7] Goyette J, Nieves DJ, Ma Y, Gaus K. How does T cell receptor
clustering impact on signal transduction? J Cell Sci 2019; 132(4):
jcs226423.
[8] Wouters MCA, Nelson BH. Prognostic significance of
tumor-infiltrating B cells and plasma cells in human cancer. Clin Cancer
Res 2018; 24(24): 6125–6135.
[9] Zhang C, Hu A, Gong M, Wang Y, Wang SF, Zhang Y, et al. Analysis
of relationship between CD3 immunohistochemical scores and tumor
differentiation degrees and prognosis in colorectal cancer. Chin Med
Biotechnol 2019; 14(4): 347–351.
[10] Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for
cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:
269–281.
[11] Wang W, Yu D, Sarnaik AA, Yu B, Hall M, Morelli D, et al.
Biomarkers on melanoma patient T cells associated with ipilimumab
treatment. J Transl Med 2012; 10: 146.
[12] Martens A, Wistuba-Hamprecht K, Yuan J, Postow MA, Wong P,
Capone M, et al. Increases in absolute lymphocytes and circulating CD4+
and CD8+ T cells are associated with positive clinical outcome of
melanoma patients treated with ipilimumab. Clin Cancer Res 2016; 22(19):
4848–4858.
[13] Fridman WH, Remark R, Goc J, Giraldo NA, Becht E, Hammond SA,
et al. The immune microenvironment: a major player in human cancers. Int
Arch Allergy Immunol 2014; 164(1): 13–26.
[14] Tjin EP, Krebbers G, Meijlink KJ, van de Kasteele W, Rosenberg
EH, Sanders J, et al. Immune-escape markers in relation to clinical
outcome of advanced melanoma patients following immunotherapy. Cancer
Immunol Res 2014; 2(6): 538–546.
[15] Rathore AS, Kumar S, Konwar R, Makker A, Negi MP, Goel MM.
CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors
of favourable survival outcome in infiltrating ductal carcinoma of
breast. Indian J Med Res 2014; 140(3): 361–369.
[16] Su Y, An X, Zhao H, Wei F, Zhang XW. The expression of Tregs
and CD8+T cells in malignant melanoma and its relationship with
prognosis. Tianjin Med J 2015; (9): 1026–1029, 1030.
[17] Zhang Q, Hao C, Cheng G, Wang L, Wang X, Li C, et al. High
CD4+T cell density is associated with poor prognosis in patients with
non-muscle-invasive bladder cancer. Int J Clin Exp Pathol 2015; 8(9):
11510–11516.
[19] Matsumoto H, Thike AA, Li H, Yeong J, Koo SL, Dent RA, et al.
Increased CD4 and CD8-positive T cell infiltrate signifies good
prognosis in a subset of triple-negative breast cancer. Breast Cancer
Res Treat 2016; 156(2): 237–247.
[19] Yang C, Cheng H, Luo G, Lu Y, Guo M, Jin K, et al. The
metastasis status and tumor burden-associated CA125 level combined with
the CD4/CD8 ratio predicts the prognosis of patients with advanced
pancreatic cancer: A new scoring system. Eur J Surg Oncol 2017; 43(11):
2112–2118.
[20] Huang Y, Ma C, Zhang Q, Ye J, Wang F, Zhang Y, et al. CD4+ and
CD8+ T cells have opposing roles in breast cancer progression and
outcome. Oncotarget 2015; 6(19): 17462–17478.
[21] Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner
P, et al. Tumour-infiltrating lymphocytes and expression of programmed
death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology
2015; 66(2): 289–299.
[22] Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et
al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor
microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;
5(200): 200ra116.
[23] Kraft S, Fernandez-Figueras MT, Richarz NA, Flaherty KT, Hoang
MP. PDL1 expression in desmoplastic melanoma is associated with tumor
aggressiveness and progression. J Am Acad Dermatol 2017; 77(3):
534–542.
[24] Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, et
al. Association between CD8+ T-cell infiltration and breast cancer
survival in 12,439 patients. Ann Oncol 2014; 25(8): 1536–1543.
[25] Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ,
Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature 2014; 515(7528): 568–571.